Medication info
Trachydia Duo Tablets 2.5/850 mg

Trachydia Duo Tablets 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu x 6)]
Approval status
Active

MFDS item code 202201610 · Approved 2022.04.19 · Insurance code 671707340

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 2.5/500 mg, 1 tablet twice daily; this may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their current doses of linagliptin and metformin. 4. Patients inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). 5. Patients inadequately controlled with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, Section 2. Do not administer to the following patients).

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug helps improve blood sugar control in patients with type 2 diabetes when used in combination with linagliptin and metformin. It is particularly effective when combined with dietary and exercise therapies, serving as an adjunct to stabilize blood sugar levels. This contributes to smoother blood sugar management and helps prevent diabetes-related complications.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 2.5/500 mg, 1 tablet twice daily; this may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their current doses of linagliptin and metformin. 4. Patients inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). 5. Patients inadequately controlled with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, Section 2. Do not administer to the following patients).

Precautions

This medication is used for the treatment of diabetes and contains two main ingredients. During the course of taking this drug, a rare side effect known as lactic acidosis may occur, which can be dangerous if lactic acid builds up in the body, so caution is required. Patients with severely impaired kidney function or liver dysfunction, pregnant or breastfeeding women, and patients with severe infections or heart failure should not take this medication. This medication can cause hypoglycemia; therefore, those taking insulin or other glucose-lowering medications should check their blood sugar levels frequently and adjust the dosage if necessary. As kidney function might decline, it is important to regularly monitor kidney function through blood tests. Additionally, serious side effects such as acute pancreatitis or bullous pemphigoid may occur while taking this medication, so immediate consultation with a doctor is necessary if abdominal pain or skin abnormalities arise. Gastrointestinal disturbances, diarrhea, abdominal pain, and vomiting may occur, but these usually improve with time. This medication should be avoided alongside alcohol due to an increased risk of lactic acidosis, and any concurrent medications should be disclosed to a doctor or pharmacist due to potential interactions. It is advisable not to use this medication during pregnancy or breastfeeding, and it is not recommended for children under 10 years old. Elderly patients may have decreased kidney function, so thorough evaluation of kidney function should be performed before administration, with regular monitoring. If undergoing surgery or radiologic examinations while taking this medication, it may be necessary to temporarily discontinue it for the procedures, so please consult with healthcare professionals. In cases of overdose, lactic acidosis may occur, necessitating immediate medical treatment, and blood dialysis may be required. This medication should be stored out of reach of children and kept away from moisture.

Side effects

  • Lactic acidosis
  • decreased vitamin B12 and deficiency
  • hypoglycemia
  • taste disturbances
  • cough
  • loss of appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
Show 127 more
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesiculobullous dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • loss of appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypercholesterolemia
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • benign prostatic hyperplasia
  • pruritus
  • confusional state
  • nocturia
  • dermatitis
  • hypertension
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • increased blood creatinine
  • facial swelling
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • subdural effusion
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is best stored at room temperature, neither too hot nor too cold, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.